From 2003 and 2013, the Food and Drug Administration and European Medicines Agency approved 62 new cancer drugs. Of these, 53 were appraised through English, French or Australian health technology assessment agencies. Researchers analyzed these assessment reports to evaluate the overall survival, quality of life and safety benefits of recently licensed cancer medicines.
Here are four study findings to know.
- Of the 53 drugs evaluated, 23 (43 percent) increased overall survival by three months or longer, six (11 percent) improved overall survival by less than three months and 16 (30 percent) were not associated with increased overall survival rate.
- Researchers found the new cancer drugs improved overall survival by an average of 3.4 months.
- Twenty-two of the drugs (42 percent) were associated with increased quality of life, while 24 (45 percent) were also linked to reduced patient safety.
- Forty-two drugs (79 percent) showed at least some improvement in overall safety, quality of life or safety.
More articles on supply chain:
Value-based supply chain management: 5 questions with Cardinal Health’s Carola Endicott and Ken Shastany
FDA shoots down Cempra’s antibiotic for pneumonia
FDA warns hospitals of battery-powered medical cart fires, explosions
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
